AdipoLABs opens Malaysian office... Full-fledged expansion into Southeast Asia

Supplied high-frequency hyperthermia cancer treatment device ‘REMISSION 1℃’ to Malaysian government hospital and held office opening event

CEO Han Sung-ho “We will do our best to ensure that all mankind can escape the pain of disease and enjoy a happy life.”

【Health News】 AdipoLABs, leading the global high-frequency hyperthermia device market, is entering into Southeast Asia in earnest.

AdipoLABs Healthcare (Co-CEOs Moses, Isaac), a Malaysian partner of AdipoLABs Co., Ltd. (CEO Han Sung-ho), which specializes in manufacturing and selling high-frequency hyperthermia devices, has expanded its office and provided high-frequency therapy to a government hospital in Malaysia. An event to celebrate the supply of hyperthermia cancer treatment device 'REMISSION 1℃' was recently held in Petaling Jaya, Malaysia.

At this event, AdipoLABs CEO Han Sung-ho, South Chungcheong Yesan Myeongji Hospital Dr. Yoo Seung-mo, KOTRA Marketing Manager in Malaysia Lee Gyeong-nam, Malaysia AdipoLABs Healthcare CEO Moses and Isaac, as well as Malaysia's former Minister of Health and Welfare Tan Sri Dr. Suleiman Mohamed, Malaysian cardiologist Dr. Lesli Lam, close to 50 Malaysian medical staff, diverse entrepreneurs, and about 100 people related to the medical center attended.

The event began with an introduction of distinguished guests and a congratulatory speech by AdipoLABs CEO Han Sung-ho, followed by a presentation on hyperthermia therapy by Malaysian Dr. Jawabi and congratulations on the office relocation.

In particular, this event served as an opportunity for AdipoLABs and Adipo LABs Healthcare's flagship medical device, ' REMISSION 1℃', a high-frequency hyperthermia cancer treatment device, to treat cancer patients not only in Korea but also in Malaysia and other countries in Southeast Asia. The event was evaluated as a meaningful event that delivered a message of hope to people.

In an interview with a Malaysian broadcaster regarding this event, CEO Han Sung-ho said, “This will be a precious opportunity for joint research between Korean and Malaysian medical staff to strive to help all people around the world escape the pain of disease and pursue a happy life.”

Meanwhile, AdipoLABs has been collaborating with Malaysia since 2018 and obtained permission for the high-frequency hyperthermia cancer treatment device ' REMISSION 1℃' from the MDA (Malaysian Food and Drug Administration) in 2020, and has also conducted clinical trials for the treatment of cancer patients at UMMC University Hospital, producing meaningful results. The company plans to expand supply to Southeast Asian countries, including Malaysia.

link: 아디포랩스, 말레이시아 사무실 오픈…동남아 진출 본격화:후생신보 (whosaeng.com)